Omega-Cold Supplementation With Free Fatty Acids for the Prevention of Respiratory Infections in Adults.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorLandspitali University Hospital

About this trial

The purpose of this study is to investigate whether fish oil containing free fatty acids affects people's susceptibility to viral infections such as colds, influenza, and COVID-19, as well as the course of these illnesses. Omega Cold is purified fish oil with 2% added free fatty acids, making it similar in that respect to less-purified fish oils. Participants aged 18-80 in generally good health will be recruited through Matís' consumer mailing list and social media advertisements. A total of 400 participants are planned: 100 in the winter of 2025-2026 and 300 in the winter of 2026-2027. Participants will be randomly assigned to two equal groups. One group will take Omega Cold orally twice a day for four months, while the other receives a placebo (vegetable oil) taken in the same way. They will not be asked to change any other habits. All participants will report weekly on their health and any cold or flu symptoms during the time they take the oil, using short questionnaires. The study is scheduled to begin in December 2025, when the oil will be sent to participants.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

to be in general good health

18 to 80 years of age

willing and able to take fish oil orally.

Disqualifiers

younger than 18 years

older than 80 years

Trial design

Design model

Parallel

Treatments tested in this trial

  • Omega-3 oil with 2% Free Fatty Acids

    Dietary supplement

    Omega-3 oil enriched with Free Fatty Acids (2%) for oral intake

  • Vegatable oil

    Dietary supplement

    Vegetable oil as placebo

Treatment groups

400 Participants
are divided into 2 treatment groups
Group A: Omega-3 oil with Free Fatty AcidsExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Respiratory infections

Participants will complete a short weekly questionnaire reporting any respiratory infection symptoms they experienced in the past seven days. If symptoms are present, they will be asked to provide additional details, including the type of symptoms, their duration, and their severity rated on numerical scales from 1 to 7 with 1 being mild and 7 being severe.

Time frame
Four months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Landspitali University Hospital

Lead sponsor

Matis ohf.

Collaborator

Lipid Pharmaceuticals ehf.

Collaborator